23 September 2024 - The application has been accepted for filing and, if approved, delgocitinib cream would become the first treatment in the US specifically indicated for adults with moderate to severe chronic hand eczema.

Leo Pharma announced today that the FDA has accepted for filing a new drug application for delgocitinib cream 20 mg/g (2%) for the treatment of adults with moderate to severe chronic hand eczema, who have had an inadequate response to, or for whom topical corticosteroids are not advisable.

Read Leo Pharma press release